SHARPE·IQStart free
Menu
TodayResearchEarningsToolsPricingSign in
MED reported Third Quarter 2026 results. The price and volatility reaction is pending.
MEDearnings

Earnings reactions, page 12

Medifast (MED) Q3 FY2026 earnings

October 26, 2026 · SharpeIQ Research Desk

Reported results

  • Revenue was $72.0 million, with 10,200 independent active earning coaches.
  • Net loss was $17.5 million, while non-GAAP adjusted net loss was $2.1 million.
  • Loss per diluted share was $1.57, compared to non-GAAP adjusted loss per diluted share of $0.19.
  • Gross profit was $50.0 million, while non-GAAP adjusted gross profit was $51.7 million.
  • Selling, general, and administrative expenses were $69.4 million, while non-GAAP adjusted SG&A was $55.6 million.
  • Adjusted EBITDA was $0.4 million, and Adjusted EBITDA excluding interest income was $1.9 million.

Guidance

  • Fourth quarter 2026 revenue expected in the range of $55 million to $75 million.
  • Fourth quarter 2026 income per share expected in the range of $0.00 to $0.25.
  • Full year 2026 revenue expected in the range of $280 million to $300 million.
  • Full year 2026 loss per share expected to range from $1.80 to $2.05.
  • Full year 2026 non-GAAP loss per share expected between $0.45 and $0.70.
  • Fourth quarter Adjusted EBITDA excluding interest income expected to range from $2 million to $6 million.
  • Full year 2026 Adjusted EBITDA excluding interest income expected to range from $10 million to $14 million.

Price and volatility reaction

Source

The figures above come from the earnings release the company filed with the SEC on 2026-10-26 (8-K, Item 2.02). Read the original filing on sec.gov.

See this live in SharpeIQ

IV rank, historical IV and the single-ticker tools. The scanner and AI research are paid plans.

Open IV Rank →